Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Phenytoin 50 mg Chewable Tablets (Ascoli vs Vega Baja)
NCT06466473Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of phenytoin in epilepsy (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-time Profile From Time Zero to the Time of Last Quantifiable Concentration at 72 hours and Maximum Observed Plasma Concentration at 72 hours. Started Jul 2024; status: completed.
02
Drugs
phenytoin
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT06466473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06466473.